CellCentric presents early clinical data at ASH
Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
- Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy
- Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients
- Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear responses seen in first cycle of dosing
Cambridge, UK, December 11th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces clinical data for the first time at the 64th American Society of Haematology (ASH) Annual Meeting, New Orleans.
To date, 26 patients with relapsed/refractory multiple myeloma (RRMM) have been treated with inobrodib as monotherapy, including seven most recently at the recommended phase 2 dose and dose schedule (RP2D). Treatment has been generally well-tolerated with the majority of on-target toxicities being mild or moderate in severity.
